AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 187 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $60,858,020 | -5.1% | 2,458,891 | +8.6% | 0.02% | 0.0% |
| Q2 2023 | $64,109,168 | +33.5% | 2,263,818 | +8.2% | 0.02% | +25.0% |
| Q1 2023 | $48,037,412 | +103391.0% | 2,091,351 | +26.5% | 0.02% | +14.3% |
| Q4 2022 | $46,417 | -99.9% | 1,653,079 | +11.8% | 0.01% | -12.5% |
| Q3 2022 | $41,811,000 | +40.4% | 1,478,389 | +10.1% | 0.02% | +45.5% |
| Q2 2022 | $29,778,000 | +1.2% | 1,343,157 | +32.9% | 0.01% | +22.2% |
| Q1 2022 | $29,420,000 | +23.4% | 1,010,616 | +39.3% | 0.01% | +28.6% |
| Q4 2021 | $23,845,000 | -4.4% | 725,401 | +34.2% | 0.01% | -12.5% |
| Q3 2021 | $24,944,000 | +59.5% | 540,498 | +90.5% | 0.01% | +60.0% |
| Q2 2021 | $15,637,000 | +4.4% | 283,773 | -2.2% | 0.01% | 0.0% |
| Q1 2021 | $14,983,000 | +18.9% | 290,206 | -0.2% | 0.01% | 0.0% |
| Q4 2020 | $12,600,000 | +10.6% | 290,761 | -10.7% | 0.01% | 0.0% |
| Q3 2020 | $11,395,000 | -37.4% | 325,606 | -4.4% | 0.01% | -37.5% |
| Q2 2020 | $18,211,000 | +33.3% | 340,526 | -11.6% | 0.01% | +14.3% |
| Q1 2020 | $13,664,000 | -14.8% | 385,146 | +14.7% | 0.01% | +16.7% |
| Q4 2019 | $16,029,000 | +92.4% | 335,675 | +30.6% | 0.01% | +100.0% |
| Q3 2019 | $8,331,000 | -4.1% | 257,020 | +47.6% | 0.00% | 0.0% |
| Q2 2019 | $8,687,000 | -28.0% | 174,160 | -2.6% | 0.00% | -40.0% |
| Q1 2019 | $12,062,000 | +43.6% | 178,887 | -1.8% | 0.01% | +25.0% |
| Q4 2018 | $8,399,000 | -23.8% | 182,150 | +27.5% | 0.00% | 0.0% |
| Q3 2018 | $11,019,000 | +29.9% | 142,895 | +41.9% | 0.00% | +33.3% |
| Q2 2018 | $8,480,000 | +35.3% | 100,695 | +31.4% | 0.00% | 0.0% |
| Q1 2018 | $6,268,000 | +77.2% | 76,644 | +52.9% | 0.00% | +50.0% |
| Q3 2015 | $3,538,000 | -40.5% | 50,137 | -6.3% | 0.00% | -50.0% |
| Q2 2015 | $5,944,000 | +36.0% | 53,514 | +15.5% | 0.00% | +33.3% |
| Q1 2015 | $4,370,000 | +6.1% | 46,329 | +26.0% | 0.00% | 0.0% |
| Q4 2014 | $4,120,000 | – | 36,774 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |